Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : True face of China -- A Modern Kaleidoscope -- Ignore unavailable to you. Want to Upgrade?

To: RealMuLan who wrote (3001)	3/14/2008 1:24:56 PM
From: hui zhou	Read Replies (1) \| Respond to of 12464

This is old one dated back 2/15. They sould be now better off for not doing anything at the first place. Those financial derivatives which Warrent Buffet called it as WMD of financial market have the potential of unlimited risk. Nobody knows how big the hole really is. According to WSJ, so far FED is pumping 1 trillion dollars of the liquidity into the system and still see not a lot of ease. All those bankers who made the quick wealth are criminals when they gave out the mortgage with no money down and no income check. But, they did create the George Bush's miracle of the "record high home ownership" when he announced on the speech to the union address last year.

To: RealMuLan who wrote (3001)	3/14/2008 1:53:58 PM
From: hui zhou	Respond to of 12464

NEW YORK (AP) -- WuXi PharmaTech Inc., a Chinese pharmaceutical and biotechnology research-and-development outsourcing company, said Wednesday its profit more than tripled in the fourth quarter, on higher revenue from its lab and research manufacturing divisions. The company earned $12.1 million, or 17 cents per American Depository Share, compared with $4 million, or 7 cents per ADS, a year ago. Revenue jumped 62 percent to $37.1 million from $22.8 million. Analysts polled by Thomson Financial expected a profit of 13 cents per share on revenue of $36.9 million. Laboratory services revenue rose 33 percent to $28.8 million while research manufacturing skyrocketed to $8.3 million. The company cited an increase in the number and scope of projects. Drug developers have been increasingly outsourcing various phases of the research and development process in a move to cut costs. Part of that shift involves overseas outsourcing. For the full year, the company earned $33.9 million, or 42 cents per share, compared with profit of $8.9 million the year before. Revenue jumped to $135.2 million from $69.9 million. In 2008, the company said it expects revenue between $280 million and $300 million, while analysts expect revenue of $237.1 million. WuXi is headquartered in Shanghai, China, and incorporated in the Cayman Islands. The company went public Aug. 9. Shares of WuXi fell 88 cents, or 4.4 percent, to close at $19.33, but jumped $2.17, or 11.2 percent, to $21.50 in aftermarket trading.